Nowadays, the gold standard for diagnosing AD is based on laboratory biomarkers (such as Aβ-42, P-tau, T-tau) and imaging techniques (MRI and PET using amyloid tracers) [6–13]. The gene discussed is MAPT; the disease is Alzheimer disease.